DIRS.INFO The most relevant business & tech news

☆ Your tax dollars are getting spent on weight-loss drugs like Ozempic, and the total is adding up
▼ + stars: | 2024-01-11 | by ( Juliana Kaplan | Ayelet Sheffey | ) www.businessinsider.com time to read: +7 min

AdvertisementConnecticut was quick to experience the impact of weight loss drugs on its economy last year. Politico reported in November that the state's employee health plan was set to spend $30 million on drugs like Ozempic and Wegovy. Comptroller Sean Scanlon told BI that that was up from $8 million in 2020. Connecticut began testing out a method to offer those seeking weight loss drugs access to a program with online tools for weight management. In North Carolina, the State Health Plan has put a moratorium on new users of GLP-1 drugs for weight loss.

Persons: Sean Scanlon, Scanlon, it's, Dale Folwell, Folwell, Shelby Livingston, Eli Lilly, that'll, Nik Modi Organizations: Service, Business, Bloomberg, Medicaid, Politico, BI, State, North, State Health, Novo Nordisk, Wall Street, University of Texas System, UT, RBC Capital Markets Locations: Connecticut, Wegovy, . Connecticut, North Carolina, Novo, Netherlands, United States

☆ What to do when 'own, don't trade' Apple and Nvidia grow into big positions
▼ + stars: | 2024-01-07 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Apple and Nvidia are "own, don't trade" stocks, so should they be kept as they are, or shrink down? First, let's address our idea of "own, don't trade" stocks. To main a diversified portfolio, we don't want any of our positions, even Apple, to get much bigger than 5-6%. That doesn't mean we don't love the name or no longer view it as an "own, don't trade," it simply means that while it is an "own, don't trade" we also still abide by the view that discipline trumps conviction (diversification and not don't be greedy being the two disciplines of focus in this case) and that overrides the own, don't trade mantra. When we say "don't trade" these two names, we stay invested in both and don't try to catch the next 10% move up or down.

Persons: Jim Cramer, Eli Lilly, Jennie, Nvidia —, Nvidia wasn't, Jim Cramer's, Jim, SeongJoon Cho Organizations: Nvidia, Broadcom, Costco, Apple, Federal Reserve, Jim Cramer's Charitable, CNBC, Apple Inc, Bloomberg, Getty Locations: Hanam, South Korea

☆ Getting hot new weight-loss drugs like Wegovy will still be a struggle in 2024
▼ + stars: | 2024-01-04 | by ( ) www.businessinsider.com time to read: +11 min

AdvertisementIf you were hoping that powerhouse weight-loss drugs like Wegovy would be easier to get in 2024, you may be disappointed. Don't expect Medicare coverage any time soonMedicare could play a major role in expanding coverage of weight-loss drugs . Americans' hunger for weight-loss drugs, and the shockwaves it's likely to send through the culture and economy, are only just beginning. He oversees the state employee health plan, which saw costs skyrocket as thousands of workers suddenly started taking weight-loss drugs. People who are already getting weight-loss drugs will be able to keep taking them.

Persons: —, Renee Rayburg, Mercer, Eli Lilly's, Jose Luis Pelaez, there's, Wegovy, Bill Coyle, ZS, Eli Lilly, David Risinger, Lilly, Risinger, Morgan Stanley, Mounjaro, They're, That's, Patrik Jonsson, Lilly USA, Coyle, Dale Folwell, Folwell Organizations: Service, Pharmaceutical, Group, Novo Nordisk's Wegovy, Mayo Clinic, University of Texas, Hennepin Healthcare, Medicare, Capital Alpha Partners, Vanderbilt University, Nordisk's Wegovy, Novo Nordisk, pharma, Nordisk's, FDA, Pharma, UBS BioPharma Conference, Walmart, Jefferies, Nordisk Locations: Mounjaro, Government, Minnesota, Minneapolis, Hennepin, ZS, U.S, Carolina, North Carolina

☆ Harvard's president resigning means more drama for other universities
▼ + stars: | 2024-01-03 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at the resignation of another Ivy League president and the knock-on effect it'll have on education in the US. The big storyIvy League issuesBrian Snyder/ReutersClaudine Gay's tenure as Harvard president wasn't long, but it won't be forgotten. Alan Garber, Harvard's provost and chief academic officer, will serve as interim president, the school's board announced. Gay is the second Ivy League president to step down in less than a month, following in the footsteps of former Penn president Elizabeth Magill. Harvard president Claudine Gay Kevin Dietsch/Getty ImagesGay and Magill's departures highlight the tension between businesses and prestigious universities and the former's influence over the latter.

Persons: —, Bob Marley, John Wick, Brian Snyder, Claudine Gay's, wasn't, Gay, Alan Garber, Harvard's, Elizabeth Magill, Magill, Sally Kornbluth, Bill Ackman, Claudine Gay Kevin Dietsch, Business Insider's Paul Squire, Lucas Jackson, Tesla, Goldman, Tyler Le, it's, Warren Buffett, Greta Thunberg, Florence Pugh, Mel Gibson, J.R.R, Tolkien, Eli Manning, Max Willcocks, Dan DeFrancesco, Diamond Naga Siu, Hallam Bullock, Jordan Parker Erb, Hayley Hudson, Lisa Ryan Organizations: Service, Ivy League, Business, Harvard, Ivy, Penn, Gay, MIT, GOP, Big Tech, Apple, Microsoft, Nvidia, Meta, Boston Consulting Group, Cushman & Wakefield, LinkedIn, SAP, Verizon Consumer Group, EV, Elon, Jiji Press, Japan Airlines, New York Locations: China, Jisoo, New York, San Diego, London, Edinburgh

☆ Here’s where to invest $50,000 in the new year, according to the pros
▼ + stars: | 2024-01-01 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +8 min

The S & P 500 rose 24% in 2023, ending the year just shy of a record closing high. The highest S & P 500 target on the Street calls for 8.7% upside from Thursday's close. A fund with exposure to small and midcap semiconductor stocks is the SPDR S & P Semiconductor ETF (XSD) . Exposure to this space can be obtained through the SPDR S & P Health Care Equipment ETF (XHE) . For these investors, Bailey likes Berkshire Hathaway , calling it a counter-cyclical sitting on a ton of cash.

Persons: Larry Adam, Raymond James, Robert Kaplan, Steven Wieting, Wieting, there's, Mike Bailey, — Bailey, Bailey, They're, Berkshire Hathaway, Eli Lilly, they're, Jack Ablin, Ablin, Rowe Price Organizations: Nasdaq, Dow Jones Industrial, CNBC Pro's, Survey, National Association for Business Economics, Dallas Federal, CNBC, Bank of America, Fed, CNBC Pro, Citi Global Wealth, Nvidia, Meta, Microsoft, P Semiconductor, P Health Care, FBB Capital Partners, Corporate, Aggregate Bond, Berkshire, Essex Property Trust, Federal Realty Trust, Rowe Price Group Locations: Essex

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
▼ + stars: | 2023-12-19 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +14 min

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. If we get a sell-off in January, Eaton is a logical place to look to buy, Jim said. Procter & Gamble : It's possible that 2024 is a better year for P & G the company than P & G the stock, Jim said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, they'll, we've, there's, he'd, Dupont De, Ed Breen, Danaher, Walt Disney, Bob Iger, Trian's Nelson Peltz, Estee Lauder, Bausch, we're, Eaton, Mary, Eli Lilly's, he's, Vimal Kapur, Kapur, We've, Eli Lilly, Mark Zuckerberg, Morgan Stanley, Morgan, Elliott, Stanley Black, Decker, TJ Maxx, Charlie Scharf, it's, Jim Cramer, Virginia Sherwood Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Broadcom, VMWare, Bausch, Bausch Health, Charitable Trust, Caterpillar, Federal, Costco Wholesale, Coterra Energy, Dupont De Nemours, Fed, Walt, Eaton Corporation, Ford, GE Healthcare, Google, Honeywell, New, Facebook, Meta, Reality Labs, Microsoft, Activision Blizzard, Nvidia, AMD, Apple, Palo Alto Networks, Procter & Gamble, Constellation Brands, Elliott Management, Constellation, Modelo, Corona, Street, TJX, TJ, Wynn Resorts, Jim Cramer's Charitable, NYSE Locations: hospitalizations, China, U.S, Palestine, Wells Fargo

☆ Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.
▼ + stars: | 2023-12-19 | by ( ) www.businessinsider.com time to read: +11 min

Inkinen said Virta can help patients quit GLP-1 drugs and keep weight off by adjusting the foods they eat to help them feel full, similar to how the drugs reduce feelings of hunger. About 82% of patients taking Wegovy experience gastrointestinal issues like nausea and diarrhea. WeightWatchers didn't provide Business Insider with published data to support its claims that it can help people keep weight off after quitting weight-loss drugs. AdvertisementHe also advises the weight-loss startup Calibrate, which tapers some patients off GLP-1 drugs after they reach a certain body-mass index. GLP-1 drugs also slash the risk of heart attacks, strokes, and cardiac-related death.

Persons: —, Michael Albert, aren't, Sami Inkinen, Inkinen, Virta, Michael Siluk, Noom's, Linda Anegawa, Carolina Rudah, tirzepatide, Mounjaro, Zepbound —, Eli Lilly, Ozempic, Wegovy, Randy Seeley, Seeley, Robyn Phelps, it's, Robert Kushner, Kushner, Florian Gaertner, It's, Albert, Lisa, she's, I'm Organizations: Service, Business, FDA, Virta, Getty, Nordisk, Michigan Nutrition Obesity Research, University of Michigan, Novo Nordisk, Northwestern University Locations: Denver, Michigan

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

☆ How every Club stock performed over the past 10 Decembers, a historically strong month
▼ + stars: | 2023-12-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

After closing at its highest level of 2023 on Friday , the first day of December, the S & P 500 fell Monday. A mixed picture is revealed when looking at how every Club stock has performed in December over the past decade. The best-performing Club stock over the past 10 Decembers is Broadcom (AVGO), which has an average gain of 7.1% in the month. Salesforce (CRM) is the worst-performing Club stock in December over the past decade, falling 4.53% on average in the month. Amazon (AMZN), Coterra Energy (CTRA) and Costco (COST) round out the bottom five December performers over the past decade.

Persons: Sam Stovall, Santa Claus, hasn't, It's, Thursday's, Estee Lauder, Eli Lilly, —, Jim Cramer's, Jim Cramer, Jim, Tayfun Organizations: GE Healthcare, Broadcom, Procter & Gamble, Wynn Resorts, WYNN, Salesforce, Ford, Palo Alto Networks, Coterra Energy, Costco, Amazon, Caterpillar, Jim Cramer's Charitable, CNBC, Wall, York Stock Exchange, Financial, Anadolu Agency, Getty Locations: Santa, Broad St, New York City, United States

☆ Jim Cramer says buy P&G, Starbucks on unwarranted pullbacks
▼ + stars: | 2023-12-05 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. But Jim Cramer urged investors to look past the headlines and stick with this solid name that boasts a $350 billion market capitalization. Club holding Eli Lilly (LLY) said Tuesday that its recently approved obesity treatment Zepbound is now available in U.S. pharmacies . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Procter, Jim, —, Eli Lilly, LLY, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Labor, Treasury, West Texas, Club, Procter, Gamble Locations: Argentina, Nigeria, China, U.S

☆ Cramer examines Tuesday's market 'mistakes,' points out underappreciated stocks
▼ + stars: | 2023-12-05 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Tuesday said he thinks Wall Street has made some poor decisions when evaluating mega cap stocks. "Look, on any given day, we're giving, getting these imperfections, these mistakes, these juvenile, uninformed moves," he said. Cramer pointed to tech giant Apple , which he said opened down on Tuesday due to a market-wide decline. But its stock changed course after the company announced its recently approved weight loss treatment Zepound is now available at pharmacies. These "mistakes" can bode well for investors who might want to buy shares of high quality stocks at lower prices.

Persons: CNBC's Jim Cramer, Cramer, Hai, Eli Lilly, Eli Lilly's, bode Organizations: Apple, Foxconn

The Ms. Foundation published research last week advocating for more financial support for women and gender nonconforming people of color leading nonprofits on the frontlines of social justices issues. “At this moment, when women and women’s bodies and gender nonconforming folks are being attacked on a daily basis, are they willing to move 10% to us?” Teresa Younger, Ms. Foundation’s president and CEO, said of other foundations. The Ms. Foundation found that many frontline organizations, like Power Rising, work across issue areas, often in tandem with other groups and in response to unfolding events. The organization advises foundations to build on trust-based giving, to support self-guided capacity building for these organizations, and to diminish grantmaking tied to specific issue areas. ___Associated Press coverage of philanthropy and nonprofits receives support through the AP’s collaboration with The Conversation US, with funding from Lilly Endowment Inc.

Persons: Alex Soros, George Soros, Trump, ” Alex Soros, Shawnda Chapman, ”, ” Teresa Younger, it’s, Laleh Ispahani, Ketanji Brown Jackson, Leah D, Daughtry, grantmaking, Ispahani, Mark Malloch, Brown Organizations: Open Society, Society, Ms, Foundation for Women, OSF, National Women's Law, Alliance for Youth, U.S, Supreme, Foundation, Associated, Lilly Endowment Inc, AP Locations: U.S

Dec 5 (Reuters) - Eli Lilly (LLY.N) on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's (NOVOb.CO) rival obesity drug Wegovy to hit around $7.5 billion. An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. When the U.S. Food and Drug Administration approved Zepbound in November, Lilly said it would launch after the U.S. Thanksgiving holiday. Lilly's obesity drug has the same active ingredient, tirzepatide, as its previously approved diabetes drug Mounjaro, which has been used off-label for weight loss since its 2022 launch.

Persons: Eli Lilly, Wegovy, danuglipron, Zepbound, Lilly, Mike Segar, Eli Lilly's, Patrick Wingrove, Manas Mishra, Khushi, Arun Koyyur, Alexander Smith, Bill Berkrot Organizations: Wall Street, Novo, Pfizer, Company, REUTERS, CVS, U.S . Food, Drug Administration, U.S, Thomson Locations: U.S, Branchburg , New Jersey, Indianapolis, New York, Bengaluru

☆ Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
▼ + stars: | 2023-12-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. High demand for the treatments has resulted in widespread shortages of Novo Nordisk 's Wegovy and diabetes drug Ozempic as well as Eli Lilly's diabetes treatment Mounjaro, pushing companies to ramp up production. Eli Lilly also said in a release that its commercial savings card program, which aims to expand access to Zepbound, is now available to patients with a prescription. Also on Tuesday, Eli Lilly said Zepbound was added to the preferred formulary, or list of covered drugs, of a major drug benefits company, Cigna . Zepbound will be added to the commercial formularies of Cigna's health-care business on Dec. 15, according to Eli Lilly.

Persons: Eli Lilly, Eli, Zepbound, Rhonda Pacheco, Eli Lilly's Organizations: Novo Nordisk, CNBC PRO Locations: U.S, Novo

☆ Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
▼ + stars: | 2023-12-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

BRAZIL - 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest company to attempt to unseat Novo Nordisk and Eli Lilly's dominance within the global weight-loss drugs market. The U.S. takeover target's early-stage technology could help crack highly prized oral obesity treatments, Roche Pharmaceuticals CEO Teresa Graham said Monday, but it may be several years before the drugs are widely available. The deal will provide Roche access to Carmot's current research and development portfolio, including all clinical and preclinical assets. Shares of the Swiss company, which have been in the doldrums this year, were up 2.25% following the news of the acquisition.

Persons: HoffmannLa Roche, Rafael Henrique, Roche, Eli Lilly's, Teresa Graham, we'll, Graham, CNBC's Julianna Tatelbaum, Eli Lilly's Mounjaro Organizations: Getty Images, Carmot Therapeutics, Novo Nordisk, U.S, Roche Pharmaceuticals, Roche Locations: BRAZIL, Swiss, California

☆ Cramer says the growing popularity of weight loss drugs brings new investing opportunities
▼ + stars: | 2023-12-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday said the increasing popularity of GLP-1 drugs — medications used to treat diabetes and obesity — has created some new investing opportunities. "Because if you really believe tons of people will take these weight loss medications, to the point where it'll have a transformational impact on the economy, well that's going to create lots of winners, too." Cramer said GLP-1 drugs can cause patients to lose muscle as well as fat, so doctors are encouraging them to consume more protein. Cramer said he also sees potential in the apparel space, with consumers likely to need new clothes to accommodate their weight loss. "When the market was ugly, everyone was worried about how much money the food companies would lose from these GLP-1 weight loss drugs," he said.

Persons: CNBC's Jim Cramer, Monday, —, Cramer, Wall, Eli Lilly, Tyson, GLP, Chip Bergh, we're Organizations: Novo Nordisk —, Tyson Foods, Jacobs

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

☆ Family of Last Child Hostages in Gaza Await Their Return
▼ + stars: | 2023-12-04 | by ( Dec. | At A.M. | ) www.usnews.com time to read: +2 min

By Eli BerlzonHOLON, Israel (Reuters) - Yosi Shnaider watched a home video on his phone from his apartment near Tel Aviv. Hamas infiltrators seized the Bibas family, along with more than 200 other people, during the Oct. 7 killing spree through southern Israeli towns that sparked the devastating war in Gaza. More than 100 hostages were freed in a week-long truce that ended on Friday, but the Bibas family - two children and their parents - were not. "And I'm thinking to myself, a young baby, small baby like Kfir, is crying. After two months in captivity, their age and ginger hair have caused the Bibas children to stand out among the scores of hostages.

Persons: Eli Berlzon HOLON, Yosi Shnaider, Ariel Bibas, Ariel, Kfir, he's, Shiri Bibas, Yarden, Shnaider, Shira Bibas, Eli Berlzon, Michal Yaakov Itzhaki, Ari Rabinovitch, Howard Goller Organizations: Hamas Locations: Israel, Tel Aviv, Gaza

Indeed, studies show that drinking alcohol is less in vogue with younger millennials and Gen Z. Mounting concern around weight loss drugs GLP-1 drugs, which mimic the action of the glucagon-like peptide-1 hormone and stimulate insulin secretion after a meal, lower blood sugar and send feeling of fullness to the brain. What's more, GLP-1 drugs are an overwhelmingly American topic, with most Europeans unaware of them or unwilling to pay high prices. In total, GLP-1 users are only a very small slice of total alcohol consumers, said Spiros Malandrakis, lead alcohol industry researcher at Euromonitor International. The most vulnerable purveyors are those that are trailing the shift in consumption, notably domestic, non-premium beer brands.

Persons: Katie Pell, Pell, wasn't, millennials, Eli Lilly's Mounjaro, Goldman Sachs, Jason English, Nadine Sarwat, Bernstein, Sarwat, Spiros Malandrakis, —, BUD YTD, who'd, Mickey Velado, Brian Sudano, Nell Healy, Healy, she's, Malandrakis, Ryan Brigden, Brigden, Sudano, Joseph Gabelli, Gabelli, Z, there's, it's, Garrett Nelson, They've, seltzer, Nelson, Molson Coors, Bud, he's Organizations: Gallup, Drugs, Nordisk's Ozempic, JPMorgan, CNBC, Euromonitor, Anheuser, Busch Inbev, Beverage Marketing, Constellation, Guinness, Corona, Heineken, Athletic Brewing Company, Heineken Holding, Carlsberg, Constellation Brands, Malandrakis, Beverage, Gabelli, Diageo, Molson Coors, Busch InBev, Molson, Anheuser Busch Locations: Brooklyn, U.S, GLP, imbibing, Angeles, Colorado, Washington, California, North Carolina, San Francisco Bay, Europe, British, Brazil, India

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ All the 'Virgin River' books, in order
▼ + stars: | 2023-12-03 | by ( Esme Mazzeo | ) www.businessinsider.com time to read: +22 min

While waiting for season six, here's the full list of books in the "Virgin River" series and the correct order to read them in. "Virgin River" (2007)"Virgin River" HarperCollins"Wanted: Midwife/nurse practitioner in Virgin River, population six hundred. "A Virgin River Christmas" (2008)"A Virgin River Christmas" HarperCollins"Last Christmas Marcie Sullivan said a final goodbye to her husband, Bobby. But the Sheridan and Riordan families have different plans for Patrick and Angie and for Christmas, Virgin River style!" "Return to Virgin River" (2020)"Return to Virgin River."

Persons: —, Robyn Carr, Melinda Monroe, she's, Mel, …, Sheridan, John, Middleton, Paige Lassiter, Semper Fidelis —, it's, Brie Sheridan, Mike Valenzuela, Virgin River's, Mike, Brie, Marcie Sullivan, Bobby, Ian Buchanan, Bobby's, Ian, Marcie, Ian doesn't, Virgin River, Vanessa Rutledge, Vanessa, Matt, Paul Haggerty, he's, Matt's, Paul, Shelby McIntyre, Luke Riordan, Shelby, Luke, Rick Sudder, Iraq —, Rick, Dan Brady, they'd, Nathaniel Jensen, Annie McCarty, Noah Kincaid, Noah, Ellie Baldwin, Ellie, Franci Duncan, Sean Riordan, Sean, — he's, Franci, Rosie, Erin Foley, Erin, Aiden Riordan, journaling, there's, Drew Foley, Sunny Archer, Sunny, Drew, Clay Tahoma, Lilly Yazhi, Lilly, There's, Clay, HarperCollins, Colin Riordan, Jillian Matlock, Jillian, Colin, Kelly, Kelly's, Lief Holbrook, Courtney, Becca Timm, Denny Cutler, Denny, Becca, Connor Danson, Leslie Petruso didn't, Connor, Leslie, Katie Malone, Katie doesn't, Dylan Childress, Dylan, Katie, Nora Crane, they've, harvesttime, Tom Cavanaugh, Nora doesn't, Nora, She's, Tom won't, Riordan, Patrick, Angie LeCroix, Jack Sheridan, she'd, Patrick Riordan, Angie, Kaylee Organizations: Netflix, Service, HarperCollins, California, Virgin, Virgin River, eBay, Bar, Marines, redwoods Locations: California, Virgin River, Virgin, Sacramento, Fallujah, Vanni, Paradise, Iraq, Los Angeles, —, Jill's, San Francisco, LA, Kelly's, Redwood, Southern California

For years, the school psychologist has been active in Muslim-Jewish interfaith dialogue, but the Israel-Hamas war left her reeling. These conversations are becoming increasingly difficult, with the war and its polarizing reverberations in America testing and straining some interfaith relationships more than ever. “We’re very courageous, you and I, because we don’t stop talking,” Seltzer told Quaizar. The Kaufman Interfaith Institute held a meeting that highlighted the challenges ahead, said Fred Stella, who is a member of the organization’s advisory board. At the Sisterhood conference, Quaizar said communicating with Jewish members has helped her through her anger.

Persons: Shireen Quaizar, ”, Quaizar, Aviva Seltzer, ” Seltzer, ” Quaizar nodded, “ We’re, Atiya Aftab, Roberta Elliott, who’s, ” They’ve, ” Aftab, She’s, she’s, Elliott, ’, “ We’ve, we’ve, Aftab, “, ” Andrea Hodos, we’re, Fred Stella, they’ve, there’s, ” Hodos, — Rawda Elbatrawish, Liora Pelavin, Jewish —, Elbatrawish, Pelavin —, who's, —, Seltzer Organizations: Aviva, ”, Los, Kaufman Interfaith Institute, ” Interfaith, Jewish, Israel Defense Forces, Sisterhood, “, Lilly Endowment Inc, AP Locations: Israel, New Brunswick , New Jersey, Salaam Shalom, America, Los Angeles, Teaneck , New Jersey, Egypt

☆ Behind the Scenes of the Most Spectacular Show On TV
▼ + stars: | 2023-12-02 | by ( Jody Rosen | ) www.nytimes.com time to read: +4 min

On the possession that followed the Lions’ touchdown, the Chiefs stalled, punting with 5:07 left. And then drama turned to farce, as Mahomes’s receivers let him down and penalties pushed the Chiefs backward. Mahomes took the snap, rolled left and launched a throw that arced across the line to gain, reaching the fingertips of the receiver Skyy Moore, who couldn’t clasp it. On the air, Tirico said: “The Detroit Lions are right there.” In the truck, Hyland’s pronouncement was less circumspect. One measure of the success of “Sunday Night Football” is how “Sunday Night Football”-ish the competing broadcasts are looking.

Persons: ” Collinsworth, Campbell, Tirico, “, Jawaan Taylor, Skycam, Hyland, Esocoff, ”, Mahomes, Skyy Moore, Chiefs weren’t, Gaudelli, “ There’s, Tom Brady, Peyton, Eli, refigures Organizations: Lions, Chiefs, “, NBC, doleful Chiefs, Detroit Lions, CBS, Fox, Fox Sports, bros, NFL Locations: Detroit

Search resuls for: "Eli Lilly

25 mentions found